Industry Applauds US FDA Plans For Novel Excipients Review Pathway, But Urges Refinement
Executive Summary
The FDA’s proposal to establish a separate review path for novel excipients draws industry plaudits and requests for fine-tuning.
You may also be interested in...
CDER Pilot Program Offers Potential New Pathway For Approval Of Novel Pharmaceutical Excipients
After decades without an approval pathway for excipients, FDA pilot program paves the way for innovation.
Excipients Group Seeks Seat At GDUFA Negotiating Table
IPEC-Americas requests an improved communications channel with the FDA and formal inclusion in talks to reauthorize the generic drug user fee program; agency says industry negotiators generally represent product manufacturers and API suppliers that are subject to user fees.
GDUFA III: Excipients Group Seeks Seat At Negotiating Table, But US FDA Skeptical
IPEC-Americas requests an improved communications channel with the FDA and formal inclusion in talks to reauthorize the generic drug user fee program; agency says industry negotiators generally represent product manufacturers and API suppliers that are subject to user fees.